

06 December 2023

Our Ref: RFI 54627

Dear

**Freedom of Information Act 2000
Information in Relation to Treatments of Myeloid and Chronic Lymphocytic
Leukaemia**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above which you requested on 06 November 2023. Please accept my apologies for the delay in responding to your request, thank you for your understanding and forbearance.

A response to each of the questions raised has been provided by the Medicine, Unscheduled Care & Cancer Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Robyn Watterson
Information Governance Officer

Q1. How many patients with Acute Myeloid Leukaemia (AML), in total, have been treated with the following therapies during the last 6 months, irrespective of start date or line of therapy?

- ***Azacitidine monotherapy***
- ***Low dose cytarabine (LoDAC) monotherapy***
- ***Venetoclax + azacitidine***
- ***Venetoclax + LoDAC***
- ***Ivosidenib***
- ***Intensive chemotherapy-based regime***
- ***Other***

A1. Please see Table 1 below:

Table 1

| Medication | Number of Patients |
|---|---------------------------|
| Azacitidine monotherapy | 2 |
| Low dose cytarabine (LoDAC) monotherapy | Nil |
| Venetoclax + azacitidine | Nil |
| Venetoclax + LoDAC | Nil |
| Ivosidenib | Nil |
| Intensive chemotherapy-based regimen | Nil |
| Other | Nil |

Q2. How many newly diagnosed patients with AML have started first line treatment with the following therapies during the last 6 months?

- ***Azacitidine monotherapy***
- ***Low dose cytarabine (LoDAC) monotherapy***
- ***Venetoclax + azacitidine***
- ***Venetoclax + LoDAC***
- ***Ivosidenib***
- ***Intensive chemotherapy-based regime***
- ***Other***

A2. Please see Table 2 below:

| Medication | Number of Patients |
|---|---------------------------|
| Azacitidine monotherapy | 2 |
| Low dose cytarabine (LoDAC) monotherapy | Nil |
| Venetoclax + azacitidine | Nil |
| Venetoclax + LoDAC | Nil |
| Ivosidenib | Nil |
| Intensive chemotherapy-based regimen | Nil |
| Other | Nil |

Q3. Of the patients with AML treated with venetoclax (venetoclax + azacitidine or venetoclax + LoDAC) in the last 6 months, how many received treatment in line with National Institute for Health and Care Excellence guidance?

A3. Not applicable.

Q4. How many with Chronic Lymphocytic Leukaemia (CLL) have received treatment with venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)? This should include patients who started treatment prior to the 6 month window

A4. There have been 6 patients who have received treatment with venetoclax.

Q5. How many patients with CLL who were new to all lines of treatment received venetoclax in the past 6 months (including venetoclax monotherapy, venetoclax + rituximab, venetoclax + obinutuzumab or venetoclax + ibrutinib)? This should include only patients who have started treatment during the 6 month window

A5. There have been 5 patients who were new to all lines of treatment who received venetoclax in the past 6 months.